Therapeutic Proteins - Fitz Flashcards

1
Q

Why are antibodies receiving considerable attention as “personalized” therapies?

A

Because of their specificity and the large number of potential targets.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What are fusion proteins?

A
  • Joining of two or more proteins together in a novel way
    • Naturally occurring (Bcr-Abl)
    • Done through recombinant DNA technology
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What are four problems with using native peptides as therapeutic proteins?

A
  1. Lack of receptor specificity/selectivity
  2. Lack of oral bioavailability
  3. Generation of neutralizing antibodies
  4. Short duration of action due to:
    1. degradation
    2. renal clearance
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What are three modifications of therapeutic proteins that improve efficacy and overcome the limitations of native peptides?

A
  • PEGylation
    • significantly increases half-life
    • “masks” the drug from the host’s immune system
    • decreased immunogenicity and antigenicity
  • Peptibodies
    • use structure of antibodies as a scaffold to build proteins that interact with a receptor without activating the immune system
  • Radiolabelled tags
    • increase the cell kill induced by antineoplastic antibodies
    • allow visualization of the extent of malignancies
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What are five advantages of antibody therapy?

A
  • Specificity (“magic bullet”)
    • increased therapeutic index
  • Large number of potential targets
    • ​​every epitope = potential therapeutic drug
  • Long-term benefit to short-term therapy
  • Diagnostic reagents - can test to see whether cells will respond before administering the drug
  • Define disease process
    • e.g. identify cancer metastases using radiolabels
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What are four characteristics of an ideal therapeutic antibody (MAB)?

A
  • High degree of affinity and specificity
  • Adequate recruitment of effector functions
    • if goal is to recruit immune system
  • Long half-life
  • Reduced systemic immunogenicity (few side effects)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What are chimeric antibodies?

A
  • Fv = mouse
  • Fc = human
  • 30%-35% mouse
  • Most side effects of all MABs
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What are humanised antibodies?

A
  • Only complementarity-determining regions (CDRs) = mouse
  • Rest of antibody = human
  • 10% mouse
  • Less side effects compared to chimeric antibodies.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

When might fully human antibodies not be as effective as humanised or chimeric version antibodies?

A

When the purpose of the antibody is to stimulate the immune system (e.g. kill cancer cells).

-since even small amounts of mouse protein evoke an immune response

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What type of therapeutic antibody is the most likely to produce the HAMA response?

A

Chimeric

  • older antibodies
  • tend to produce more side effects
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

How are therapeutic antibodies administered? Why?

A
  • Given IV
  • Extremely long half-lives (3-6+ months)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What are five types of common side effects to MAB treatments?

A
  • Immediate Response/Hypersensitivity
    • fever, headache, anaphylaxis
  • Type III Hypersensitivity Reactions
    • HAMA (human anti-mouse antibody) = hypersensitivity → kidney damage → serum sickness
  • Cytokine release syndrome (“cytokine storm”)
    • shaking chills, fever, arthralgia, diarrhea, vomiting, hypotension, and respiratory distress
  • Infections
    • especially when antibodies suppress immune system (reactivation of TB)
  • Unknown effects
    • immunization, carcinogensis, fertility, pregnancy, breast feeding (anti-TNFalpha = Thalidomide)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What are the two general strategies in the design of MABs and fusion proteins?

A
  1. Inhibit protein function
  2. Recruit immune system to attack and destroy cells that are selectively expressing a particular protein
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What are three common themes for multiple antibodies?

A
  • Same target may be active in different diseases
    • same drug may be used to treat different diseases (e.g. VEGF in colon cancer & macular degeneration)
  • Different antibodies (humanized vs. chimeric) may be used against the same target
    • due to many different drug companies
  • Cytotoxic agents can be used to increase efficacy
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What do cytokine interactions with target cells often result in?

A

Cascade effects

(cause release of other endogenous cytokines)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What are the two major disadvantages of cytokine therapy?

A
  1. Extremely short half-lives
  2. Complicated nature of the biological response (potent biological modifiers)
17
Q

What are common side effects of cytokine therapy?

A
  • anorexia
  • fever
  • flu-like symptoms
  • fatigue
  • general malaise
18
Q

What are unique/life-threatening side effects of IL-2 cytokine therapy?

A
  • Thrombocytopenia
  • Shock
  • Respiratory distress
  • Coma
  • FATAL HYPOTENSION
19
Q

What is the most important (but not sole) regulator of proliferation of committed red blood cell progenitors that is a member of the JAK/STAT superfamily and is produced in the kidneys?

A

Erythropoietin

20
Q

What are the three erythroid growth factors that we need to know?

A
  1. Erythropoietin
  2. Darbepoetin
  3. MPEG-Epoetin
21
Q

What is the half-life of Erythropoietin?

A

Relatively short: IV administration 3-4x per week

(DARB - given weekly, MPEG-EPO - given biweekly)

22
Q

What are the two main therapeutic uses of Erythroid growth factors?

A
  • ***Anemia
    • chronic kidney disease (will need iron/folate supplementation)
    • primary bone marrow disorders & secondary anemias
  • high-risk surgery
    • anticipating significant blood loss
23
Q

In what two situations should you NOT GIVE therapeutic erythroid growth factors?

A
  • Athletes (banned by olympic committee)
  • Patients with anemia due to cancer chemotherapy (should not give MPEG-Epoetin mainly)
24
Q

What are the possible side effects of therapeutic erythroid growth factors?

A
  • Thrombosis (life-threatening)
  • Hypertension (serious, common)
  • Increased tumor growth (rare)
  • Allergic reaction (rare)
25
What are the three myeloid growth factors we need to know?
1. Filgrastim (G-CSF) 2. Pegfilgrastim 3. Sagramostim (GM-CSF)
26
What cells does Filgrastim (G-CSF) regulate the production of?
Neutrophils
27
What cells do Sagramostim (GM-CSF) stimulate?
Myelopoiesis (GM-CSF): - Neutrophils - Monocytes
28
What are the therapeutic uses of myeloid growth factors?
* Cancer chemotherapy-induced neutropenia * Congenital neutropenia * Cyclic neutropenia * Myelodysplasia * Aplastic anemia
29
What are the possible side effects of Filgrastim/Pegfilgrastim?
* Mild-moderate bone pain (common) * Allergic reactions (rare) * Splenic rupture (rare)
30
What are the possible side effects of Sargramostim?
* **Capillary leak syndrome** (common, serious) * Moderate-severe bone pain (common) * Fever, malaise, arthralgia/myalgia (common) * Allergic reaction (rare)
31
What are the two therapeutic megakaryocyte growth factors we need to know?
1. Interleukin 11 2. Romiplostim
32
What cell does Interleukin 11 increase the production of?
Platelets
33
What is so unique about the nonimmunogenic peptide agonist of the thrombopoietin receptor, Romiplostim?
It is the first approved "peptibody".
34
Why is Thrombopoietin not used as a therapeutic megakaryocyte growth factor?
Caused production of autoantibodies.
35
What is the half-life of Romiplostim?
3-4 days (longer in pts with thrombocytopenia) (shorter in pts whose platelet counts have recovered)
36
What are the potential side effects of therapeutic Interleukin 11?
* **Atrial fibrillation** (common, serious) * Hypokalemia (rare) * Fatigue, headache, dizziness, dyspnea, anemia, mild-moderate edema (common) * DOES NOT CAUSE FEVER!
37
What are the potential side effects of Romiplostim?
* Mild headache on the day of administration * Otherwise well tolerated